RxDoctor Payments Data

Dawn Pike

Nurse Practitioner · West Columbia, SCNPI 1669572632

Payments from drug & device makers

$2,041in general payments, 2019–2025

Across 120 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$601
  • Coloplast$579
  • Sumitomo Pharma America, Inc.$229
  • Medtronic$123
  • Astellas Pharma US Inc$99
  • Urovant Sciences Inc$78
  • plus $332 from 10 others

What the payments were for

  • Food & beverage$1,94295%
  • Education$995%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie27$601
Coloplast57$579
Sumitomo Pharma America, Inc.10$229
Medtronic2$123
Astellas Pharma US Inc1$99
Urovant Sciences Inc5$78
Merck2$58
Antares Pharma, Inc.4$56
ABC Home Medical Supply, Inc.2$42
Boston Scientific2$38
Teleflex LLC2$37
Halozyme Inc2$27
Convatec Inc.1$22
Axonics, Inc.1$21
Hollister Incorporated1$18
SRS Medical Systems, Inc.1$14

How this compares

$2,041 in reported general payments places this provider in the 85th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$138,958
Medicare patients
1,009
Services billed
6,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron158$114,168
GemtesaVibegron82$56,365
Mirabegron ErMirabegron31$18,460
Tamsulosin Hcl656$13,914
Solifenacin Succinate261$11,493
Dutasteride102$5,380
Finasteride225$4,127
Methenamine Hippurate34$3,408
Tadalafil50$2,946
Trospium Chloride ErTrospium Chloride21$2,938
NitrofurantoinNitrofurantoin Macrocrystal54$2,848
Alfuzosin Hcl ErAlfuzosin Hcl89$2,709
Fesoterodine Fumarate ErFesoterodine Fumarate31$2,410
Trimethoprim35$2,094
Silodosin14$1,875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$99$114,168158 claims
Sumitomo Pharma America, Inc.Gemtesa$229$56,36582 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →